ArticleArthroplasty today2025
Efficacy of Repeated High-Dose Versus Intermediate-Dose Intravenous Dexamethasone in Reducing Pain After Bilateral Total Knee Arthroplasty: A Randomized Clinical Trial.
Article in Arthroplasty today, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal dose of intravenous (IV) dexamethasone for bilateral one-stage total knee arthroplasty (BTKA) remains controversial. Therefore, this study aimed to evaluate the efficacy of administering repeated high-dose IV dexamethasone compared to repeated intermediate-dose dexamethasone for BTKA. Methods: In this randomized, triple-blinded, clinical trial of 46 patients who underwent BTKA were randomly divided into 2 groups. The high-dose group received 16 mg of IV dexamethasone before surgical incision and a repeated dose at 24 hours postoperatively. The intermediate-dose group received 8 mg of dexamethasone at the same time points. The outcomes measured included visual analog scale (VAS) for pain intensity during motion and at rest, morphine consumption (MC), knee flexion angle, knee strength, knee circumference, timed up and go, frequency of postoperative nausea and vomiting, high-sensitivity C-reactive protein, blood glucose levels, and complications. Results: No significant differences were found between groups regarding VAS, except the high-dose group reporting lower VAS during motion only at 24 hours postoperatively (mean difference: -0.9, Conclusions: Repeated high-dose IV dexamethasone provides comparable clinical outcomes to the intermediate-dose IV dexamethasone. Therefore, intermediate-dose IV dexamethasone may be sufficient for controlling pain and inflammatory response in BTKA setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.